Arasay, Michelle U.
HRN: 21-38-39 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/24/2022
CEFUROXIME 1.5GM (VIAL)
06/24/2022
07/01/2022
IVT
1.5g
Q8
Endometritis S/P NSVD
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes